Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis

BACKGROUND: Finerenone and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), while the relative efficacy has not been determined. METHODS: The databases of PubMed, Embase and Cochrane were...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xuefeng, Wu, Hongli, Peng, Huifang, Jiang, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797657/
https://www.ncbi.nlm.nih.gov/pubmed/36589800
http://dx.doi.org/10.3389/fendo.2022.1078686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797657/
https://www.ncbi.nlm.nih.gov/pubmed/36589800
http://dx.doi.org/10.3389/fendo.2022.1078686

Ejemplares similares